| Therapeutic | Avelumab |
| Target | CD274 |
| Heavy Chain | EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYIMMWVRQAPGKGLEWVSSIYPSGGITFYADTVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARIKLGTVTTVDYWGQGTLVTVSS |
| Light Chain | QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTRVFGTGTKVTVL |
| 100% seqID Fv Structure | 4nki%3AHL%2F5grj%3AHL [Fvs: ] |
| 99% seqID Fv Structure | None |
| 95-98% seqID Fv Structure | None |
| 100% seqID Structure | 4nki%3AHL%2F5grj%3AHL [Fvs: ] |
Follow these links to our prediction tools:
| Format | Whole mAb |
| Isotype | G1 |
| Highest Clinical Trial (August '23) | Approved |
| Estimated Status (August '23) | Active |
| Recorded Developmental Technology | Human Phage Display |
| INN Year Proposed | 2015 |
| INN Year Recommended | 2016 |
| Companies Involved | AIO Studien gGmbH%3BArray BioPharma%3BChong Kun Dang%3BDana-Farber Cancer Institute%3BDebiopharm%3BeFFECTOR Therapeutics%3BEMD Serono%3BForty Seven%3BFred Hutchinson Cancer Research Center%3BGachon University Gil Medical Center%3BHellenic Cooperative Oncology Group%3BHospices Civils de Lyon%3BJohannes Gutenberg-University Mainz%3BM. D. Anderson Cancer Center%3BMerck KGaA%3BNational Cancer Institute %28USA%29%3BNational Cancer Institute Slovakia%3BNetherlands Cancer Institute%3BPfizer%3BSidney Kimmel Comprehensive Cancer Center at Johns Hopkins%3BSyndax Pharmaceuticals%3BTransgene%3BUniversity College London%3BUniversity of Birmingham%3BUniversity of California San Diego%3BUniversity of Iowa%3BVaccinex%3BVanderbilt-Ingram Cancer Center%3BVAXIMM%3BVerastem Oncology%3BWashington University School of Medicine |
| Conditions Approved | Merkel cell carcinoma%3BUrogenital cancer%3BRenal cell carcinoma |
| Conditions Active | Breast cancer%3BDiffuse large B cell lymphoma%3BGastric cancer%3BHead and neck cancer%3BNon-small cell lung cancer%3BOvarian cancer%3BBladder cancer%3BEndometrial cancer%3BFallopian tube cancer%3BGerm cell and embryonal neoplasms%3BGestational trophoblastic disease%3BGlioblastoma%3BHaemangiosarcoma%3BIntestinal cancer%3BLeiomyosarcoma%3BNasopharyngeal cancer%3BNeuroendocrine tumours%3BOsteosarcoma%3BPeripheral T-cell lymphoma%3BPeritoneal cancer%3BProstate cancer%3BRecurrent respiratory papillomatosis%3BSmall cell lung cancer%3BSolid tumours%3BSquamous cell cancer%3BThymoma%3BLiposarcoma%3BLymphoma%3BOropharyngeal cancer%3BPancreatic cancer%3BAcute myeloid leukaemia%3BFollicular lymphoma%3BHodgkin%27s disease%3BLiver cancer%3BMeningioma%3BBone metastases%3BAnal cancer%3BCervical cancer%3BVulvovaginal cancer%3BMeningioma |
| Conditions Discontinued | na |
| Notes | Avelumab and Bintrafusp have identical V domains |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]
